Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.5%

1 terminated/withdrawn out of 65 trials

Success Rate

97.2%

+10.7% vs industry average

Late-Stage Pipeline

6%

4 trials in Phase 3/4

Results Transparency

0%

0 of 35 completed trials have results

Key Signals

12 recruiting

Enrollment Performance

Analytics

N/A
42(70.0%)
Phase 2
14(23.3%)
Phase 3
3(5.0%)
Phase 4
1(1.7%)
60Total
N/A(42)
Phase 2(14)
Phase 3(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (65)

Showing 20 of 65 trials
NCT07560397Not ApplicableNot Yet Recruiting

Feasibility Study on the Implementation of a Supervised, Home-based Adapted Physical Activity Program for Patients With Head and Neck Cancer

Role: lead

NCT07499765Not ApplicableRecruiting

Benefits of Formalized Care Support Program Following Acute Leukemia Diagnosis

Role: lead

NCT06089941Active Not Recruiting

Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas

Role: lead

NCT03896412Not ApplicableCompleted

Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma

Role: lead

NCT02426697Phase 3Completed

Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy

Role: lead

NCT03952052Not ApplicableCompleted

Detection of Recurrent Mutations in Waldenström's Disease

Role: lead

NCT02821936Not ApplicableCompleted

Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer

Role: lead

NCT02617745Phase 2Completed

Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid

Role: lead

NCT06141772Not ApplicableCompleted

Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy

Role: lead

NCT05675982Not ApplicableActive Not Recruiting

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells

Role: lead

NCT03832348Not ApplicableCompleted

Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment

Role: lead

NCT05934929Not ApplicableActive Not Recruiting

Contribution of Residual Tumour DNA Testing on the Surgical Bed

Role: lead

NCT06450548Not ApplicableRecruiting

Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA

Role: lead

NCT05146180Not ApplicableRecruiting

Interest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis

Role: lead

NCT04528420Not ApplicableRecruiting

Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer

Role: lead

NCT06879704Not ApplicableRecruiting

Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

Role: lead

NCT04031534Phase 2Completed

Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma

Role: lead

NCT02490891Phase 2Completed

Study of the Angiogenesis by PET/CT in Patients With Lymphoma

Role: lead

NCT03594149Phase 3Completed

Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients

Role: lead

NCT02815137Not ApplicableCompleted

Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma

Role: lead